Table 1.

baseline characteristics of study cohorts (n = 72)

Variable	Frequency	%
Age, in years
<50	24	33.3
≥50	48	66.7
Mean age ± SD = 54.6 ± 10.7 years
Menopausal status
Premenopausal	33	45.8
Postmenopausal	39	54.2
Parity
Low parity (≤1)	23	31.9
High parity (≥2)	49	68.1
Median parity (IQR) = 2.0 (1.0, 4.0)
Body Mass Index (BMI), in kg/m2
≤25.0	37	51.4
>25.0	35	48.6
Median BMI (IQR) = 24.7 (22.1, 28.9) kg/m2
Co-morbidity
No	55	76.4
Yes	17	23.6
Pre-treatment CA125 levels, in U/Ml
<250.0	25	34.7
≥250.0	47	65.3
Median CA125 (IQR) = 437.0 (144.0, 924.5) U/mL
Type of cytoreductive surgery
Optimal	37	51.4
Suboptimal	35	48.6
Presence of significant ascites
No	37	51.4
Yes	35	48.6
FIGO stage
Early (I-II)	19	26.4
Advanced (III-IV)	53	73.6
Tumour grade
Low grade (grade I)	20	27.8
High grade (grade II-III)	52	72.2
Histological type
Serous	48	66.7
Non-serous	24	33.3
Type of primary treatment
Primary debulking	39	54.2
Neoadjuvant chemotherapy	33	45.8
Recurrence within 36-months
Yes	55	76.4
No	17	23.6
Median PFS (IQR) = 15.0 (8.0, 29.5) months

Abbreviations: SD, standard deviation; IQR, interquartile range; FIGO, international federation of obstetrics and gynaecology